



Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 1, 2022

MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 1, 2022--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 2:00 p.m. Eastern Time.

The webcast link is available only for those who are attending the BTIG conference.

About Personalis, Inc.

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The [Personalis NeXT Platform®](#) is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. To enable cancer sequencing, the Personalis [Clinical Laboratory](#) was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ([@PersonalisInc](#)).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220201006054/en/): <https://www.businesswire.com/news/home/20220201006054/en/>

Investor Relations Contact:

Caroline Corner
investors@personalis.com
415-202-5678

Media Contact:

Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

Source: Personalis, Inc.